RBP-02

RBP-02 is a preclinical-stage drug candidate being developed by ReBio Technologies for the treatment of retinoblastoma, a rare and aggressive form of eye cancer that primarily affects infants and young children. While the specific molecular target and modality have not been publicly disclosed, the program is part of ReBio's specialized portfolio in ocular oncology. RBP-02 likely utilizes the company's proprietary SiSu® (Sustained-release, In-Situ forming) technology, which is designed to deliver therapeutic agents via a single intravitreal injection that forms a drug-releasing depot in the eye, potentially improving treatment outcomes and reducing the need for frequent clinical interventions.